LYEL
Lyell Immunopharma, Inc. · Healthcare
21.78
0.41%(+0.09)
Close26.46
21.49%(+4.68)
After HoursLast Updated: — ET
52W L: $7.6552W H: $45.00
$22.19
CHG-1.47 (-6.21%)
H$27.75
L$17.87
VOL1.8M
LYEL (1h)
Lyell Immunopharma, Inc. · Healthcare
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time.
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares Mangoceuticals and Lyell Immunopharma's
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.
SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Lyell has since commenced patient dosing in the first-of-its-kind Phase 3 head-to-head CAR T-cell randomized controlled clinical trial of rondecabtagene autoleucel (ronde-cel) versus investigator's choice of axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with disease progression on at least one prior line of therapy (PiNACLE-H2H). Lyell has dosed seven new patients with metastatic colorectal cancer (mCRC) with LYL273, an enhanced guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate, since its November 2025 acquisition, without dose-limiting toxicity and including dose escalation to Dose Level 3.
Stock News U.S. pump prices jump on war-driven supply shock: Average U.S. gasoline rose to about $3.54/gal, the highest since midâ2024, as the U.S.âIran con
Stock News Oil pulls back from $100+: Brent fell roughly 8% toward $91 as President Trump indicated the Iran conflict could end âvery soon,â while Saudi Ara
Shah Smital
officer: Chief Fin. and Bus. Officer
140,000 SH @ $25.50
2026-03-09
Shah Smital
0 SH @ $0.00
2026-03-09
ARCH Venture Partners IX, LLC
10 percent owner
488,090 SH @ $25.61
2026-03-06
ARCH Venture Fund XIII, L.P.
10 percent owner
488,090 SH @ $25.61
2026-03-06
Seely Lynn
director, officer: President and CEO
7,455 SH @ $23.39
2026-02-11
Hill Stephen J.
officer: Chief Operating Officer
1,236 SH @ $23.39
2026-02-11
Lee Gary K.
officer: Chief Scientific Officer
1,671 SH @ $23.39
2026-02-11
Hill Stephen J.
officer: Chief Operating Officer
65,000 SH @ $23.71
2026-02-10